Described are recombinant AAV vectors characterized in that they carry
capsid protein modification(s) resulting in a reduced or eliminated
heparin binding function. The AAV vectors of the present invention are
particularly suitable for gene therapy by systemic application, since (a)
transduction of the liver is eliminated or at least drastically reduced
and (b) the transduction efficiency of non-hepatic tissues is increased.